CAS 17019-92-0: 11-KETO-BETA-BOSWELLIC ACID

11-​Keto-​β-​boswellic acid

Carboxylic acid with additional oxygen functions

11-Keto-beta-boswellic acid, a novel Nrf2 activator, and a selective 5-lipoxygenase (5-LOX) inhibitor; it exerts dose dependent cardioprotective effect manifested by dose-dependent reduction in serum lactate dehydrogenase; and it can increase the Nrf2 and HO-1 expression, which provides protection against oxygen and glucose deprivation (OGD)-induced oxidative insult. 11-Keto-beta-boswellic acid possesses significant anti-inflammatory, and anti-tumoral activities.

11-Keto-beta-boswellic acid is a pentacyclic triterpenoid, which is derived from the resin of Boswellia species, commonly known as frankincense. This compound is characterized by its unique structure, which plays a significant role in its biological activities. As a bioactive compound, its mode of action primarily involves the inhibition of specific enzymes such as 5-lipoxygenase, which is crucial in the leukotriene biosynthesis pathway. This inhibition leads to a reduction in the synthesis of pro-inflammatory mediators, thereby exerting anti-inflammatory effects. The applications of 11-Keto-beta-boswellic acid are extensive in the fields of pharmacology and medical research. It is primarily utilized in the investigation of inflammatory disorders, including rheumatoid arthritis, asthma, and inflammatory bowel disease. Researchers are also exploring its potential in oncology, as it exhibits properties that may inhibit tumor growth. The compound's ability to modulate inflammatory pathways highlights its promise as a therapeutic agent in chronic inflammation-related diseases.

11-keto-beta-boswellic acid analytical standard provided with w/w absolute assay, to be used for quantitative titration.

11-Keto-beta-boswellic acid, a novel Nrf2 activator, and a selective 5-lipoxygenase (5-LOX) inhibitor, exerts dose dependent cardioprotective effect manifested.